Research on breast cancer aimed at identifying unique antigens and at developing antibodies

Ziel

The department of Oncology of Crucell Holland BV, lead by Renate Zwijsen (PhD) is actively involved in the development and the commercialisation of monoclonal human antibodies, applying its MAbstract target discovery and antibody development technology and its PER.C6 human cell line technology for high-yielding antibody production.

The department of Oncology intends on initiating a breast cancer research program aimed specifically at identifying antigens that are uniquely expressed in breast cancer and, thereafter, at developing human antibodies that selectively bind to these identified antigens. For this project, Crucell Holland BV has an exclusive arrangement with the University Medical Centre of Utrecht (UMC Utrecht) through which Crucell Holland BV will have a constant supply of fresh breast cancer tissue samples to be used for this research project.

Wissenschaftliches Gebiet

medical and health sciencesclinical medicineoncologybreast cancer

Programm/Programme

FP5-HUMAN POTENTIAL - Programme for research, technological development and demonstration on "Improving the human research potential and the socio-economic knowledge base" (1998-2002)

Thema/Themen

Data not available

Aufforderung zur Vorschlagseinreichung

IHP-MCHI-01-1
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

Data not available

Koordinator

CRUCELL HOLLAND B.V.

EU-Beitrag

Keine Daten

Adresse

Archimedesweg 4
LEIDEN
Niederlande

Gesamtkosten